Tricida, Inc. financial data

Industry
Pharmaceutical Preparations
Location
7000 Shoreline Court, Suite 201, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 501 % -27.7%
Debt-to-equity -253 % -171%
Return On Equity 159 %
Return On Assets -104 % -35.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58M shares +15%
Common Stock, Shares, Outstanding 55.7M shares +10.4%
Common Stock, Value, Issued 56K USD +12%
Weighted Average Number of Shares Outstanding, Basic 58M shares +15%
Weighted Average Number of Shares Outstanding, Diluted 58M shares +15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 92.1M USD -13%
Operating Income (Loss) -124M USD +20.4%
Net Income (Loss) Attributable to Parent -134M USD +26.2%
Earnings Per Share, Basic -2.36 USD/shares +34.6%
Earnings Per Share, Diluted -2.36 USD/shares +34.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 17.7M USD +4.45%
Assets, Current 82.5M USD -45.4%
Property, Plant and Equipment, Net 541K USD -35.3%
Operating Lease, Right-of-Use Asset 10.9M USD -13.7%
Assets 93.9M USD -43%
Accounts Payable, Current 4.4M USD +34.8%
Accrued Liabilities, Current 9.74M USD -50.7%
Liabilities, Current 16.9M USD -34.2%
Operating Lease, Liability, Noncurrent 9.85M USD -16.2%
Other Liabilities, Noncurrent 7.85M USD
Liabilities 230M USD +41.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -428K USD -456%
Retained Earnings (Accumulated Deficit) -882M USD -16%
Stockholders' Equity Attributable to Parent -136M USD -7256%
Liabilities and Equity 93.9M USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.4M USD +14.8%
Net Cash Provided by (Used in) Financing Activities -190K USD +99.8%
Net Cash Provided by (Used in) Investing Activities 23.2M USD +37.9%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 55.7M shares +10.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.4M USD +96.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.7M USD +4.45%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Depreciation 81K USD -39.6%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -134M USD +26.2%
Operating Lease, Liability, Current 2.8M USD +2.98%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Additional Paid in Capital 746M USD -2.11%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 10M USD -49.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%